{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T14:13:24Z","timestamp":1779804804045,"version":"3.53.1"},"reference-count":127,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Children"],"abstract":"<jats:p>Sickle cell disease is the most common monogenetic disease worldwide and affects millions of children and adults. While supportive care practices have improved life expectancy, particularly in high income countries, sickle cell disease typically has adverse impact on quality of life and reduced life expectancy. As a result, patients and providers are increasingly seeking information regarding curative and transformative therapies and advocating for improved global access. This review will describe allogeneic hematopoietic cell transplantation eligibility, approaches to transplant, short and long-term outcomes and key supportive care considerations for providers who care for patients with sickle cell disease.<\/jats:p>","DOI":"10.3390\/children13060741","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T13:28:21Z","timestamp":1779802101000},"page":"741","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hematopoietic Cell Transplantation for Sickle Cell Disease"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9380-4347","authenticated-orcid":false,"given":"Gregory Michael Taylor","family":"Guilcher","sequence":"first","affiliation":[{"name":"Departments of Oncology and Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1056\/NEJM198409203111207","article-title":"Bone-marrow transplantation in a patient with sickle-cell anemia","volume":"311","author":"Johnson","year":"1984","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2016-10-745711","article-title":"Sickle cell disease: An international survey of results of HLA-identical sibling hematopoietic stem cell transplantation","volume":"129","author":"Gluckman","year":"2017","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/s41390-024-03566-w","article-title":"Fostering a healthier generation of children with sickle cell disease through advancements in care","volume":"97","author":"Franco","year":"2025","journal-title":"Pediatr. Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1182\/bloodadvances.2022009202","article-title":"Long-term survival with sickle cell disease: A nationwide cohort study of Medicare and Medicaid beneficiaries","volume":"7","author":"Jiao","year":"2023","journal-title":"Blood Adv."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e29099","DOI":"10.1002\/pbc.29099","article-title":"Decision making for hematopoietic stem cell transplantation in pediatric, adolescent, and young adult patients with a hemoglobinopathy-Shared or not?","volume":"68","author":"Mekelenkamp","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.bbmt.2017.08.034","article-title":"Ethical Challenges in Hematopoietic Cell Transplantation for Sickle Cell Disease","volume":"24","author":"Nickel","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_7","unstructured":"(2026, May 07). Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients with Sickle Cell Disease (WeDecide), Available online: https:\/\/clinicaltrials.gov\/NCT06941389."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1182\/blood.2019000821","article-title":"How I treat sickle cell disease with hematopoietic cell transplantation","volume":"134","author":"Stenger","year":"2019","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/03630269.2026.2614371","article-title":"Implementation of a Dedicated Hematopoietic Stem Cell Transplant Program for Sickle Cell Disease in Lagos, Nigeria: Challenges and Opportunities","volume":"50","author":"Akinsete","year":"2026","journal-title":"Hemoglobin"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41409-020-0983-5","article-title":"Setting up and sustaining blood and marrow transplant services for children in middle-income economies: An experience-driven position paper on behalf of the EBMT PDWP","volume":"56","author":"Faulkner","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1182\/blood-2025-1051","article-title":"Longterm survival and late effects following hematopoietic cell transplantation for sickle cell disease into a modern era: A center for international blood and marrow transplant research (CIBMTR) analysis","volume":"146","author":"Stenger","year":"2025","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e71464","DOI":"10.1002\/hsr2.71464","article-title":"Advancing Hematopoietic Stem Cell Transplantation (HSCT) in Africa: A Pathway to Curing Hematological Disorders","volume":"8","author":"Ogunniyi","year":"2025","journal-title":"Health Sci. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e244","DOI":"10.1016\/S2352-3026(24)00322-3","article-title":"Establishment of a haematopoietic cell transplantation programme for children with sickle cell disease in Tanzania","volume":"12","author":"Giglio","year":"2025","journal-title":"Lancet Haematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1182\/bloodadvances.2021004394C","article-title":"American Society of Hematology 2021 guidelines for sickle cell disease: Stem cell transplantation","volume":"5","author":"Kanter","year":"2021","journal-title":"Blood Adv."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3324\/haematol.2013.099747","article-title":"Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: Indications and management recommendations from an international expert panel","volume":"99","author":"Angelucci","year":"2014","journal-title":"Haematologica"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/ajh.21846","article-title":"Development and validation of a pediatric severity index for sickle cell patients","volume":"85","author":"Heijboer","year":"2010","journal-title":"Am. J. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2147\/CEOR.S276121","article-title":"Development of a Severity Classification System for Sickle Cell Disease","volume":"12","author":"Shah","year":"2020","journal-title":"ClinicoEcon. Outcomes Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/ejh.12011","article-title":"Sickle cell disease severity scoring: A yet unsolved problem","volume":"89","author":"Coelho","year":"2012","journal-title":"Eur. J. Haematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e28861","DOI":"10.1002\/pbc.28861","article-title":"Hematopoietic stem cell transplant referral patterns for children with sickle cell disease vary among pediatric hematologist\/oncologists\u2019 practice focus: A Sickle Cell Transplant Advocacy and Research Alliance (STAR) study","volume":"68","author":"Meier","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e543","DOI":"10.3324\/haematol.2019.216788","article-title":"Risk factors and outcomes according to age at transplantation with an HLA-identical sibling for sickle cell disease","volume":"104","author":"Cappelli","year":"2019","journal-title":"Haematologica"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1182\/blood.2020005687","article-title":"Risk score to predict event-free survival after hematopoietic cell transplant for sickle cell disease","volume":"136","author":"Brazauskas","year":"2020","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e585","DOI":"10.1016\/S2352-3026(19)30154-1","article-title":"Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: A retrospective multicentre, cohort study","volume":"6","author":"Eapen","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e29893","DOI":"10.1002\/pbc.29927","article-title":"Neuropsychological, behavioral, and quality-of-life outcomes in children and adolescents with sickle cell disease treated with nonmyeloablative matched sibling donor hematopoietic cell transplantation: A case series","volume":"69","author":"Monagel","year":"2022","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"47.e1","DOI":"10.1016\/j.jtct.2022.10.012","article-title":"Long-Term Organ Function After HCT for SCD: A Report from the Sickle Cell Transplant Advocacy and Research Alliance","volume":"29","author":"Stenger","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e28568","DOI":"10.1002\/pbc.28568","article-title":"Stable renal function in children and adolescents with sickle cell disease after nonmyeloablative hematopoietic stem cell transplantation","volume":"67","author":"Pedersen","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e29927","DOI":"10.1002\/pbc.29927","article-title":"Pulmonary function in children and adolescents with sickle cell disease after nonmyeloablative hematopoietic cell transplantation","volume":"69","author":"Monagel","year":"2022","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jtct.2023.12.079","article-title":"Preservation of Pulmonary Function Following Hematopoietic Cell Transplant for Sickle Cell Disease: A STAR Study","volume":"30","author":"Horan","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"ref_28","first-page":"1918","article-title":"Impact of bone marrow transplantation for symptomatic sickle cell disease: An interim report","volume":"95","author":"Walters","year":"2000","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/bjh.12737","article-title":"Haematopoietic stem cell transplantation for severe sickle cell disease in childhood: A single centre experience of 50 patients","volume":"165","author":"Dedeken","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3324\/haematol.2018.213207","article-title":"Long-term event-free survival, chimerism and fertility outcomes in 234 patients with sickle-cell anemia younger than 30 years after myeloablative conditioning and matched-sibling transplantation in France","volume":"105","author":"Bernaudin","year":"2020","journal-title":"Haematologica"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/bmt.2014.84","article-title":"Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease","volume":"49","author":"Bhatia","year":"2014","journal-title":"Bone Marrow Transplant."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/ajh.24183","article-title":"Successful matched sibling donor marrow transplantation following reduced intensity conditioning in children with hemoglobinopathies","volume":"90","author":"King","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1182\/blood-2021-144454","article-title":"Nonmyeloablative HLA-Identical Sibling Donor Transplantation for Children and Young Adults with Sickle Cell Disease: Interim Results of the SUN Multicenter Phase II Trial","volume":"138","author":"Nickel","year":"2021","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood-2016-05-715870","article-title":"A trial of unrelated donor marrow transplantation for children with severe sickle cell disease","volume":"128","author":"Shenoy","year":"2016","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"826.e1","DOI":"10.1016\/j.jtct.2025.06.015","article-title":"Impact of Abatacept Inclusive Graft-Versus-Host Disease Prophylaxis in Pediatric Stem Cell Transplantation for Hemoglobinopathy","volume":"31","author":"Shah","year":"2025","journal-title":"Transplant. Cell. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.bbmt.2019.12.085","article-title":"Abatacept for Gvhd Prophylaxis after Hematopoietic Cell Transplantation (HCT) for Pediatric Sickle Cell Disease (SCD): A Sickle Cell Transplant Advocacy and Research Alliance (STAR) Trial","volume":"26","author":"Chaudhury","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jamapediatrics.2019.4715","article-title":"Familial Haploidentical Stem Cell Transplant in Children and Adolescents with High-Risk Sickle Cell Disease: A Phase 2 Clinical Trial","volume":"174","author":"Cairo","year":"2020","journal-title":"JAMA Pediatr."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1182\/blood.2023023301","article-title":"An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease","volume":"143","author":"Kassim","year":"2024","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1182\/blood-2025-164","article-title":"Reduced intensity haploidentical bone marrow transplantation in children with severe sickle cell disease (SCD): BMT CTN 1507","volume":"146","author":"Walters","year":"2025","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1182\/bloodadvances.2025017413","article-title":"Bone marrow transplantation for sickle cell disease using post-transplantation cyclophosphamide and 400 cGy TBI","volume":"10","author":"Goldenberg","year":"2026","journal-title":"Blood Adv."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/ajh.25401","article-title":"Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study","volume":"94","author":"Krishnamurti","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jtct.2025.02.021","article-title":"Two Nonmyeloablative HLA-Matched Related Donor Allogeneic Hematopoietic Cell Transplantation Regimens in Patients with Severe Sickle Cell Disease","volume":"31","author":"Inam","year":"2025","journal-title":"Transplant. Cell. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjh.17311","article-title":"Non-myeloablative human leukocyte antigen-matched related donor transplantation in sickle cell disease: Outcomes from three independent centres","volume":"192","author":"Alzahrani","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"EVIDoa2400192","DOI":"10.1056\/EVIDoa2400192","article-title":"Haploidentical Bone Marrow Transplantation for Sickle Cell Disease","volume":"4","author":"Kassim","year":"2025","journal-title":"NEJM Evid."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1038\/s41409-021-01302-0","article-title":"Successful mismatched hematopoietic stem cell transplantation for pediatric hemoglobinopathy by using ATG and post-transplant cyclophosphamide","volume":"56","author":"Oostenbrink","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.bbmt.2017.10.030","article-title":"Outcomes of Unrelated Donor Stem Cell Transplantion with Post-Transplant Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Patients with Severe Sickle Cell Disease","volume":"24","author":"Rangarajan","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/j.bbmt.2020.07.015","article-title":"HLA-Matched Unrelated Donors for Patients with Sickle Cell Disease: Results of International Donor Searches","volume":"26","author":"Torres","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1002\/pbc.25439","article-title":"Allogeneic donor availability for hematopoietic stem cell transplantation in children with sickle cell disease","volume":"62","author":"Justus","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.hemonc.2020.01.002","article-title":"Haploidentical bone marrow transplant with posttransplant cyclophosphamide for sickle cell disease: An update","volume":"13","author":"Patel","year":"2020","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.bbmt.2018.11.027","article-title":"Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide Plus Thiotepa Improves Donor Engraftment in Patients with Sickle Cell Anemia: Results of an International Learning Collaborative","volume":"25","author":"Dhedin","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41409-019-0550-0","article-title":"Haploidentical CD3 or alpha\/beta T-cell depleted HSCT in advanced stage sickle cell disease","volume":"54","author":"Foell","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bmt.1701291","article-title":"Haematopoietic stem cell transplantation for sickle cell anaemia: The first 50 patients transplanted in Belgium","volume":"22","author":"Vermylen","year":"1998","journal-title":"Bone Marrow Transplant."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1182\/blood-2007-03-079665","article-title":"Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease","volume":"110","author":"Bernaudin","year":"2007","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jtct.2022.10.008","article-title":"Enrollment Lessons from a Biological Assignment Study of Marrow Transplantation versus Standard Care for Adolescents and Young Adults with Sickle Cell Disease: Considerations for Future Gene and Cellular Therapy Trials","volume":"29","author":"Krishnamurti","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/ajh.27360","article-title":"Azathioprine\/hydroxyurea preconditioning prior to nonmyeloablative matched sibling donor hematopoietic stem cell transplantation in adults with sickle cell disease: A prospective observational cohort study","volume":"99","author":"Dovern","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1182\/hematology.2022000371","article-title":"Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease","volume":"2022","author":"Fitzhugh","year":"2022","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Gondek, L.P., Sheehan, V.A., and Fitzhugh, C.D. (2022). Clonal Hematopoiesis and the Risk of Hematologic Malignancies after Curative Therapies for Sickle Cell Disease. J. Clin. Med., 11.","DOI":"10.3390\/jcm11113160"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"S315","DOI":"10.1016\/S2666-6367(21)00404-8","article-title":"Conditioning Regimen Trends in Hematopoietic Stem Cell Transplant for Sickle Cell Disease: A Survey from the Sickle Cell Transplant Advocacy and Research Alliance (STAR) Consortium","volume":"27","author":"Abraham","year":"2021","journal-title":"Transplant. Cell. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"594.e1","DOI":"10.1016\/j.jtct.2025.05.004","article-title":"Comparison of Regimens Used for Allogeneic Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease","volume":"31","author":"Prior","year":"2025","journal-title":"Transplant. Cell. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"912.e1","DOI":"10.1016\/j.jtct.2024.06.029","article-title":"Reproductive Health Assessment and Reports of Fertility Counseling in Pediatric and Adolescent Patients with Sickle Cell Disease After Hematopoietic Cell Transplantation","volume":"30","author":"George","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jtct.2023.08.003","article-title":"RIC does not do the trick to prevent the high infertility risk in females with sickle cell disease after hematopoietic cell transplantation","volume":"29","author":"Nickel","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4583","DOI":"10.1182\/blood-2019-121952","article-title":"Results of Unrelated Donor Hematopoietic Stem Cell Transplantation for Sickle Cell Disease in Europe on Behalf of Paediatric Diseases (PDWP) and Inborn Errors Working Parties (IEWP) of the EBMT","volume":"134","author":"Gluckman","year":"2019","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.bbmt.2017.05.027","article-title":"Unrelated Umbilical Cord Blood Transplantation for Sickle Cell Disease Following Reduced-Intensity Conditioning: Results of a Phase I Trial","volume":"23","author":"Abraham","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"103554","DOI":"10.1016\/j.transci.2022.103554","article-title":"Umbilical cord blood as a hematopoietic stem cell source in transplantation for pediatric sickle cell disease: Current challenges and strategies","volume":"61","author":"Malhotra","year":"2022","journal-title":"Transfus. Apher. Sci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","article-title":"Peripheral-blood stem cells versus bone marrow from unrelated donors","volume":"367","author":"Anasetti","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/j.bbmt.2018.08.010","article-title":"Bone Marrow versus Peripheral Blood from Unrelated Donors for Children and Adolescents with Acute Leukemia","volume":"24","author":"Keesler","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2014.7192","article-title":"Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype","volume":"312","author":"Hsieh","year":"2014","journal-title":"JAMA"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/ejh.14083","article-title":"Feasibility of peripheral blood stem cell collection from sickle cell trait donors with an intensified G-CSF regimen","volume":"111","author":"Mohrez","year":"2023","journal-title":"Eur. J. Haematol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1182\/bloodadvances.2024014836","article-title":"Improved survival with model-based dosing of antithymocyte globulin in pediatric hematopoietic cell transplantation","volume":"9","author":"Admiraal","year":"2025","journal-title":"Blood Adv."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1182\/bloodadvances.2024015094","article-title":"A prospective clinical trial of GVHD prophylaxis with posttransplant cyclophosphamide and abatacept","volume":"9","author":"Koura","year":"2025","journal-title":"Blood Adv."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1182\/blood-2017-03-772392","article-title":"At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT","volume":"130","author":"Fitzhugh","year":"2017","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.bbmt.2017.08.038","article-title":"Relationship between Mixed Donor-Recipient Chimerism and Disease Recurrence after Hematopoietic Cell Transplantation for Sickle Cell Disease","volume":"23","author":"Abraham","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Guilcher, G.M.T., Dalal, S., Suresh, T., Yelamali, A.R., Arora, J., Aljayyousi, H., Bhatia, M., Haight, A.E., Khandelwal, P., and Khoury, R. (Transplant. Cell. Ther., 2026). Long-term Follow-up After Mixed Donor Myeloid Chimerism at 1 Year Post Transplantation for Sickle Cell Disease, Transplant. Cell. Ther., in press.","DOI":"10.1016\/j.jtct.2026.02.012"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Nadaf, R., Lee, H., Bonney, D., Hanasoge-Nataraj, R., Senthil, S., Horgan, C., Guiver, M., Poulton, K., and Wynn, R. (2024). Mixed T-Cell Chimerism Following Hematopoietic Cell Transplantation for Non-Malignant Disorders Is Common, Facilitates Anti-Viral Immunity, and Is Not Associated with Graft Failure in Pediatric Patients. Cells, 13.","DOI":"10.3390\/cells13242119"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1182\/bloodadvances.2024013953","article-title":"A road map for uniform, comprehensive long-term follow-up after curative therapy for sickle cell disease","volume":"9","author":"Shenoy","year":"2025","journal-title":"Blood Adv."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/MOH.0000000000000786","article-title":"Mixed donor chimerism following stem cell transplantation for sickle cell disease","volume":"30","author":"Shah","year":"2023","journal-title":"Curr. Opin. Hematol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1182\/blood-2005-04-1376","article-title":"Evidence for ineffective erythropoiesis in severe sickle cell disease","volume":"106","author":"Wu","year":"2005","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/ajh.27627","article-title":"Recipient Cells Are the Source of Hematologic Malignancies After Graft Failure and Mixed Chimerism in Adults With SCD","volume":"100","author":"Ali","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"American Academy of Pediatrics, and Committee on Bioethics (2010). Children as hematopoietic stem cell donors. Pediatrics, 125, 392\u2013404.","DOI":"10.1542\/peds.2009-3078"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/s41409-022-01749-9","article-title":"CD34-selected stem cell boost as therapy for late graft rejection following allogeneic transplantation for sickle cell disease","volume":"57","author":"Rangarajan","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"877.e1","DOI":"10.1016\/j.jtct.2021.07.012","article-title":"Outcomes with CD34-Selected Stem Cell Boost for Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis","volume":"27","author":"Shahzad","year":"2021","journal-title":"Transplant. Cell. Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/08880018.2021.2013369","article-title":"Post-transplant CD34+ selected stem cell boost as an intervention for declining mixed chimerism following reduced intensity conditioning allogeneic stem cell transplant in children and young adults with sickle cell disease: A case series","volume":"39","author":"Ngwube","year":"2022","journal-title":"Pediatr. Hematol. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"S200","DOI":"10.1016\/j.jtct.2025.12.275","article-title":"Alpha Beta (\u03b1\/\u03b2) T cell Depleted Second HCT Is Effective for Impending Secondary Graft Failure after Reduced Intensity and Nonmyeloablative MSD HCT in Sickle Cell Disease","volume":"32","author":"Mandava","year":"2026","journal-title":"Transplant. Cell. Ther."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJM199608083350601","article-title":"Bone marrow transplantation for sickle cell disease","volume":"335","author":"Walters","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Meier, E.R., Allistair, A., and Fasano, R.M. (2017). Sickle Cell Disease and Hematopoietic Stem Cell Transplantation, Springer Nature.","DOI":"10.1007\/978-3-319-62328-3"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/pbc.25904","article-title":"Improved Splenic Function After Hematopoietic Stem Cell Transplant for Sickle Cell Disease","volume":"63","author":"Nickel","year":"2016","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.bbmt.2009.10.005","article-title":"Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease","volume":"16","author":"Walters","year":"2010","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1038\/s41409-021-01298-7","article-title":"Stable to improved cardiac and pulmonary function in children with high-risk sickle cell disease following haploidentical stem cell transplantation","volume":"56","author":"Friedman","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1513\/AnnalsATS.202309-771OC","article-title":"Pulmonary Function after Nonmyeloablative Hematopoietic Cell Transplant for Sickle Cell Disease","volume":"21","author":"Ruhl","year":"2024","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/j.jtct.2025.12.091","article-title":"Long-Term Cardiac Function Remains Stable to Improved Following Curative Allogeneic Hematopoietic Cell Transplantation for Pediatric Sickle Cell Disease: A STAR Analysis","volume":"32","author":"Sukkar","year":"2026","journal-title":"Transplant. Cell. Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"231.e1","DOI":"10.1016\/j.jtct.2023.11.007","article-title":"Improvement in Cardiac Morphology Demonstrated by Cardiac Magnetic Resonance Imaging and Echocardiography after Haploidentical Hematopoietic Cell Transplantation in Adults with Sickle Cell Disease","volume":"30","author":"Limerick","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/s41409-025-02550-0","article-title":"Kidney function after nonmyeloablative hematopoietic cell transplant for sickle cell disease","volume":"60","author":"Limerick","year":"2025","journal-title":"Bone Marrow Transplant."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"e210191","DOI":"10.1212\/WNL.0000000000210191","article-title":"Cerebral Hemodynamic Responses to Disease-Modifying and Curative Sickle Cell Disease Therapies","volume":"104","author":"Aumann","year":"2025","journal-title":"Neurology"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1018.e1","DOI":"10.1016\/j.jtct.2021.08.026","article-title":"Low Rates of Cerebral Infarction after Hematopoietic Stem Cell Transplantation in Patients with Sickle Cell Disease at High Risk for Stroke","volume":"27","author":"Carpenter","year":"2021","journal-title":"Transplant. Cell. Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/bjh.17178","article-title":"Improved stenosis outcome in stroke-free sickle cell anemia children after transplantation compared to chronic transfusion","volume":"193","author":"Verlhac","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"8","DOI":"10.14740\/jh949","article-title":"Hematopoietic Stem Cell Transplantation Stabilizes Cerebral Vasculopathy in High-Risk Pediatric Sickle Cell Disease Patients: Evidence From a Referral Transplant Center","volume":"11","author":"Siddiqui","year":"2022","journal-title":"J. Hematol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1182\/blood.2022016618","article-title":"Normalization of cerebral hemodynamics after hematopoietic stem cell transplant in children with sickle cell disease","volume":"141","author":"Hulbert","year":"2023","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s42466-022-00175-y","article-title":"Transcranial Doppler sonography and the effect of haematopoietic stem cell transplantation in sickle cell disease","volume":"4","author":"Thurn","year":"2022","journal-title":"Neurol. Res. Pract."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Braniecki, S., Vichinsky, E., Walters, M.C., Shenoy, S., Shi, Q., Moore, T.B., Talano, J.A., Parsons, S.K., Flower, A., and Panarella, A. (2024). Neurocognitive outcome in children with sickle cell disease after myeloimmunoablative conditioning and haploidentical hematopoietic stem cell transplantation: A non-randomized clinical trial. Front. Neurol., 15.","DOI":"10.3389\/fneur.2024.1263373"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1080\/09602011.2023.2238948","article-title":"Longitudinal neurocognitive effects of nonmyeloablative hematopoietic stem cell transplant among older adolescents and adults with sickle cell disease: A description and comparison with sibling donors","volume":"34","author":"Carlson","year":"2024","journal-title":"Neuropsychol. Rehabil."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Keane, E.P., Adri, F.N., Larizza, I.S., Monahan, J.A., Song, M.T., Boardman, A.C., Schaefer, D.A., Wu, J.H., Conway, S., and Brown, L. (Transplant. Cell. Ther., 2026). Caring for the Hematopoietic Stem Cell Transplantation Population: Clinician Perspectives on Challenges and Opportunities in Psychosocial Care Delivery, Transplant. Cell. Ther., in press.","DOI":"10.1016\/j.jtct.2026.01.033"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.bcmd.2015.03.012","article-title":"The effects of hydroxyurea and bone marrow transplant on Anti-Mullerian hormone (AMH) levels in females with sickle cell anemia","volume":"55","author":"Elchuri","year":"2015","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"770.e1","DOI":"10.1016\/j.jtct.2022.08.014","article-title":"Comparison of Anti-Mullerian Hormone Levels Pre- and Post-Hematopoietic Cell Transplantation in Pediatric and Adolescent Females with Sickle Cell Disease","volume":"28","author":"George","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"e30276","DOI":"10.1002\/pbc.30276","article-title":"Parental perspective on the risk of infertility and fertility preservation options for children and adolescents with sickle cell disease considering hematopoietic stem cell transplantation","volume":"70","author":"Sinha","year":"2023","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/S2352-3026(22)00353-2","article-title":"Expecting more: The case for incorporating fertility services into comprehensive sickle cell disease care","volume":"10","author":"Pecker","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Jarisch, A., Rotz, S.J., Cattoni, A., Courbiere, B., Lundy, S.D., Orwig, K.E., Poirot, C., Dalle, J.H., Phelan, R., and Diesch-Furlanetto, T. (Transplant. Cell. Ther., 2026). Fertility Preservation in 2026: Current Landscape in Europe and the United States for Children and Adolescents Undergoing Hematopoietic Stem Cell Transplantation\u2014Recommendations on Behalf of the Westhafen Intercontinental Group, Transplant. Cell. Ther., in press.","DOI":"10.1038\/s41409-026-02861-w"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"e575","DOI":"10.1097\/MPH.0000000000001782","article-title":"Longitudinal Description of Gonadal Function in Sickle-cell Patients Treated with Hematopoietic Stem Cell Transplant Using Alkylator-based Conditioning Regimens","volume":"42","author":"Elchuri","year":"2020","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"531.e1","DOI":"10.1016\/j.jtct.2023.05.004","article-title":"Female Reproductive Health Outcomes after Hematopoietic Cell Transplantation for Sickle Cell Disease: Is Reduced Intensity Better Than Myeloablative Conditioning?","volume":"29","author":"Meacham","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Nickel, R.S., Maher, J.Y., Hsieh, M.H., Davis, M.F., Hsieh, M.M., and Pecker, L.H. (2022). Fertility after Curative Therapy for Sickle Cell Disease: A Comprehensive Review to Guide Care. J. Clin. Med., 11.","DOI":"10.3390\/jcm11092318"},{"key":"ref_110","first-page":"53","article-title":"A method to identify California\u2019s sickle-cell disease population and its linkage to the California Cancer Registry","volume":"39","author":"Brown","year":"2012","journal-title":"J. Regist. Manag."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1200\/JCO.22.01203","article-title":"Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease","volume":"41","author":"Eapen","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1182\/blood.2022017960","article-title":"Increased incidence of hematologic malignancies in SCD after HCT in adults with graft failure and mixed chimerism","volume":"140","author":"Lawal","year":"2022","journal-title":"Blood"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1080\/17474086.2024.2423368","article-title":"Late effects of hemopoietic stem cell transplant for sickle cell disease: Monitoring and management","volume":"17","author":"Goldenberg","year":"2024","journal-title":"Expert. Rev. Hematol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"7414","DOI":"10.1182\/blood-2024-206235","article-title":"Avascular Necrosis (AVN) Outcomes in Allogeneic Stem Cell Transplant Recipients","volume":"144","author":"Shoaib","year":"2024","journal-title":"Blood"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1182\/blood-2025-178","article-title":"The need for a subsequent HCT is a late & continuous risk and with significant impact in overall survival in haemoaglobinopathies: Real-world data from 2000\u20132022. An analysis of the European society for blood and marrow transplantation (EBMT) hemoglobinopathy working party","volume":"146","author":"Baronciani","year":"2025","journal-title":"Blood"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e174","DOI":"10.1016\/j.bbmt.2019.01.008","article-title":"Functional and Radiologic Assessment of the Brain after Reduced-Intensity Unrelated Donor Transplantation for Severe Sickle Cell Disease: Blood and Marrow Transplant Clinical Trials Network Study 0601","volume":"25","author":"King","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.bbmt.2014.12.007","article-title":"Health-related quality of life after allogeneic hematopoietic stem cell transplantation for sickle cell disease","volume":"21","author":"Bhatia","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1182\/blood-2025-4278","article-title":"Children and adolescents with sickle cell disease demonstrate improved health-related quality of life and low decisional regret after hematopoietic cell transplantation: A sickle cell transplant advocacy and research alliance (STAR) study","volume":"146","author":"Guilcher","year":"2025","journal-title":"Blood"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.jtct.2025.12.033","article-title":"Outcomes Following Graft Failure and Second Subsequent Allogeneic Hematopoietic Cell Transplant in Patients with Sickle Cell Disease: A Multicenter Study","volume":"32","author":"Rangarajan","year":"2026","journal-title":"Transplant. Cell. Ther."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene Autotemcel for Severe Sickle Cell Disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood-2024-199743","article-title":"An Update on Lovotibeglogene Autotemcel (Lovo-cel) Clinical Trials for Sickle Cell Disease (SCD) and Analysis of Early Predictors of Response to Lovo-Cel","volume":"144","author":"Kanter","year":"2024","journal-title":"Blood"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/ajh.26741","article-title":"Lovo-cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB-206 study","volume":"98","author":"Kanter","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1016\/j.ymthe.2025.03.016","article-title":"Current and future treatments for sickle cell disease: From hematopoietic stem cell transplantation to in vivo gene therapy","volume":"33","author":"Ball","year":"2025","journal-title":"Mol. Ther."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1182\/blood-2025-1049","article-title":"Enhanced CD34+ cell mobilizations, collections, and comparable safety profile with fixed-dose versus weight-based plerixafor dosing in patients with sickle cell disease receiving autologous CD34+ base-edited hematopoietic stem cells (BEAM-101) in the ongoing BEACON study","volume":"146","author":"Frangoul","year":"2025","journal-title":"Blood"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e633","DOI":"10.1016\/S2352-3026(23)00096-0","article-title":"Defining global strategies to improve outcomes in sickle cell disease: A Lancet Haematology Commission","volume":"10","author":"Piel","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_126","unstructured":"(2026, March 16). CTTC Practice Guidelines and Recommendations. Algorithm for Medical Eligibility for Curative and Transformative Therapies for patients with Sickle Cell Disease and Transfusion Dependent Thalassemia in Canada. Available online: https:\/\/www.cttcanada.org\/page\/PracticeGuidelines."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1007\/s12325-023-02545-7","article-title":"Economic and Clinical Burden of Managing Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in the United States","volume":"40","author":"Udeze","year":"2023","journal-title":"Adv. Ther."}],"container-title":["Children"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9067\/13\/6\/741\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T13:50:59Z","timestamp":1779803459000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9067\/13\/6\/741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":127,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["children13060741"],"URL":"https:\/\/doi.org\/10.3390\/children13060741","relation":{},"ISSN":["2227-9067"],"issn-type":[{"value":"2227-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]}}}